An international survey across 101 medical institutions found substantial variation in infection prophylaxis and surveillance practices for patients receiving bispecific antibodies and CAR-T cell therapies. The results highlight differences in how centers define monitoring intensity, prophylactic regimens, and response thresholds. For biotech teams developing or supporting immunotherapies, the survey provides a concrete operations checklist: heterogeneity in infection management can influence clinical outcomes, cross-trial comparability, and real-world adoption. Although survey-based, the findings reinforce the need for standardized, mechanism-informed infection prevention strategies tied to product- and patient-specific risk factors rather than local custom alone.
Get the Daily Brief